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NMR-based evaluation of the metabolic proﬁle
and response to dichloroacetate of human
prostate cancer cells
Mithun Kailavasana, Ishtiaq Rehmanb, Steven Reynoldsa, Adriana Bucura,
Gillian Tozerb and Martyn Paleya*
The aim of this study was to evaluate the metabolic proﬁle of human prostate cancer cells that have different
metastatic potential and to determine their response to dichloroacetate (DCA) using NMR technology. Two isogenic
human prostate cancer cell lines, differing in their metastatic potential [LNCaP (poorly metastatic) and LNCaP-LN3
(highly metastatic)], were studied. Metabolite ratios from NMR spectral integrals acquired at a ﬁeld strength of
9.4 T using a 5-mm broadband probe with an NMR-compatible bioreactor were compared in the presence and
absence of the pyruvate dehydrogenase kinase inhibitor DCA. Lactate dehydrogenase (LDH) isoenzymes were
assessed by zymography. Following the treatment of cells with 50mM DCA, there was a signiﬁcant reduction in
the lactate/choline, lactate/creatine, lactate/alanine and the combined lactate/(choline + creatine + alanine) ratios
in LNCaP-LN3 cells relative to LNCaP cells. No signiﬁcant changes in metabolite ratios were found in LNCaP cells
following DCA treatment. As expected, LDH zymography assays showed an absence of the LDH-B subunit in
LNCaP-LN3 cells, whereas both LDH-A and LDH-B subunits were present in LNCaP cells. DCA was shown to
signiﬁcantly modify the metabolite ratios in highly metastatic LNCaP-LN3 cells, but not in poorly metastatic LNCaP
cells. This effect was probably related to the absence of the LDH-B subunit in LNCaP-LN3 cells, and could have a
bearing on cancer treatment with DCA and related compounds. © 2014 The Authors. NMR in Biomedicine published
by John Wiley & Sons, Ltd.
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INTRODUCTION
Worldwide, prostate cancer is the second most common cancer
diagnosis (1). In 2012, the American Cancer Society estimated that
around 241 740 American men were diagnosed with prostate
cancer and 28 170men died from the disease (1,2). The vast major-
ity of cancer-related deaths were caused by progression of the
disease from being conﬁned to the organ to disseminated meta-
static disease (3). As a result of the heterogeneity of the biological
behaviour of prostate cancer, a major challenge facing clinicians in
the management of patients is distinguishing between the subset
of patients in whom the disease will progress to become a lethal
metastatic disease and the majority of patients in whom the
tumour will remain organ conﬁned and relatively indolent.
Current methods of detection and diagnosis of prostate
cancer are based on a triad of serum prostate-speciﬁc antigen
(PSA) measurements, digital rectal examination (DRE) and
histological assessment of trans-rectal ultrasound (TRUS)-guided
needle biopsy material (4,5). Although PSA is a US Food and
Drug Administration-approved biomarker, and the most widely
used biomarker for prostate cancer detection, its use is associ-
ated with a high degree of false-positive and false-negative test
results (6). Therefore, PSA testing has led to an over-diagnosis
and over-treatment of otherwise clinically insigniﬁcant disease
(7). Thus, there is an urgent need for additional biomarkers that
can improve the diagnostic speciﬁcity of PSA, and reliably
predict the likelihood of disease progression.
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In the presence of oxygen, normal cells derive most of their
energy in the form of ATP from glycolysis, coupled with
mitochondrial oxidative phosphorylation, in a process that yields
a total of 36 ATP molecules per molecule of glucose consumed,
in addition to CO2 and water (8). However, when the supply of
oxygen is limited, pyruvate is converted to lactate by a reaction
catalysed by lactate dehydrogenase (LDH) (Fig. 1). LDH is a
tetrameric enzyme, consisting of different combinations of two
subunits (LDH-A and LDH-B, encoded by two different genes) to
form ﬁve different isoenzymes LDH-1–LDH-5: LDH-B4 (LDH-1);
LDH-B3:A1 (LDH-2); LDH-B2:A2 (LDH-3), LDH-B1:A3 (LDH-4) and
LDH-A4 (LDH-5) subunits (9,10).
In contrast with normal cells, cancer cells derive a higher
proportion of their energy from lactic acid fermentation, even
in the presence of oxygen, despite the fact that it is a highly
inefﬁcient process. A high rate of aerobic glycolysis, followed
by lactic acid fermentation in the cytosol, was ﬁrst described in
cancer cells by Otto Warburg in the 1920s, and is now known
as the Warburg effect (11). Conversion of pyruvate to lactate
regenerates the oxidised form of nicotinamide adenine dinucle-
otide (NAD+), necessary as a co-factor for continued glycolysis
and associated anabolic pathways, which are needed for tumour
cell proliferation. Thus, the altered metabolism seen in cancer
cells is thought to confer a survival advantage to the cells (12).
A number of other metabolic changes have been reported in
cancer cells. For example, the MYC gene that regulates mitochon-
drial glutamine metabolism is frequently dysregulated in human
cancers (13). Thus, cancer cells exhibit increased glutamine metab-
olism, and the resulting products are used as precursors for the
synthesis of other amino acids, such as proline, arginine and
ornithine (14). Other studies have estimated that around 60% of
glutamine in cancer cells is used to promote lactate and alanine
production (12). Cancer cells have also been shown to have
elevated de novo fatty acid biosynthesis, which has been associ-
ated with evasion from cellular apoptosis (12). However, certain
cancer cells may display signs of increased fatty acid oxidation,
as it can provide an alternative energy source (15,16). There is
good evidence that increased lactate metabolism is associated
with a higher rate of metastasis formation, and that the targeting
of lactate production with drugs, such as dichloroacetate (DCA)
(see below), could be effective against metastases (17).
Collectively, a number of metabolic changes have been
associated with neoplastic transformation, in particular increased
intracellular glucose metabolism, increased glycolytic enzyme
activities (including LDH activity), glutaminolytic activity and de
novo fatty acid synthesis (18), as well as increased choline,
phosphocholine and alanine (19–21). Pyruvate can be converted
into alanine via the transaminase reaction, which is in rapid equi-
librium. The lactate/alanine (Lac/Ala) ratio is associated with a
cellular redox state because the conversion of pyruvate to lactate
and alanine is coupled with NAD+ and NADH reactions (22).
Thus, the Lac/Ala ratio reﬂects the NADH/NAD+ equilibrium (23).
DCA is a small molecule of 151Da with high bioavailability
that has undergone clinical trials for the treatment of a number
of cancer types. For instance, a published Phase 1 clinical trial
studied the effect of DCA in patients suffering from glioblastoma,
and there have been calls for a Phase 2 trial (24). In vitro, DCA has
been shown to inhibit pyruvate dehydrogenase kinase (PDK),
including the PDKII isoform. PDKII is one of four isoforms of
PDK, that is expressed in most tissues and has the highest
sensitivity to DCA (24). An inhibition of PDK is associated with
an increase in pyruvate dehydrogenase activity, and the conse-
quences of this inhibition are thought to be an increase in the
ﬂux of pyruvate into the mitochondria of the cell, thereby
promoting oxidative phosphorylation over lactate production
and restoring a ‘normal’metabolic state in cancer cells. However,
although these in vitro and in vivo studies have suggested a ben-
eﬁcial role for DCA in the treatment of human cancers (25–27),
side effects from toxicity have hindered development. Studies
in mice have demonstrated neurotoxicity and, in high doses,
DCA was found to be carcinogenic (26). Currently, DCA remains
a useful prototype PDK inhibitor for use in preclinical studies
until more speciﬁc agents become available. Tumour response
to DCA is highly variable, depending on the tumour model used,
thus highlighting the need for predictive biomarkers that can
predict the therapeutic response to PDK inhibitors.
The aim of the present study was to employ NMR techniques
to characterise the metabolic proﬁle of two isogeneic human
prostate cancer cell lines, which differ in their in vivo metastatic
potentials [LNCaP (poorly metastatic) and LNCaP-LN3 (highly
metastatic)], in an effort to understand the biochemical basis of
prostate cancer progression and to identify candidate bio-
markers of progression (27). In addition, we hypothesised that
DCA would be most effective in altering the metabolic proﬁle
of LNCaP-LN3 cells, as their glycolytic enzyme proﬁle suggests
a dependence on pyruvate to lactate metabolism (17).
METHODS
Cell lines and culture
The human prostate cancer cell line LNCaP was purchased from
the American Type Culture Collection (ATCC) (http://www.
lgcstandards-atcc.org/). The human LNCaP-LN3 prostate cancer
cell line was a kind gift from Dr Curtis Pettaway (MD Anderson
Cancer Center, Houston, TX, USA) (28).
Both cell lines were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (high glucose +GlutaMAX) supplemented with
10% fetal calf serum (FCS) and 1 ×penicillin/streptomycin (P/S)
(Life Technologies, Paisley, Scotland, UK). Cells were cultured in
T175cm2 ﬂasks, incubated at 37 °C with a mixture of 5% CO2–
Figure 1. Simpliﬁed diagram containing the cellular anaerobic glyco-
lytic pathway and tricarboxylic acid (TCA) cycle: note the regeneration
of NAD+ through the glycolysis process. Some of the steps between
fructose 1,6-phosphate (fructose 1,6-PO4) and phosphoenolpyruvate
have been omitted for clarity.
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95% air, and passaged routinely when they reached approxi-
mately 80–90% conﬂuence.
DCA treatment of cells
A ﬁnal concentration of 50mM DCA was used in the culture me-
dium above, and the cells were exposed for 24 h.
Growth rates
Growth rates were measured for both the LNCaP and LNCaP-
LN3 cells over 4 days under standard growth conditions as
described above. Around 1 × 104 cells were seeded into each
well of a 24-well plate and counted using a haemocytometer
under a microscope (× 10 objective), as described below.
LDH zymography assays
Zymography for LDH isoenzymes was performed using cellulose
acetate membranes (Titan III, 94×76mm2, Helena Biosciences,
Gateshead, Tyne and Wear, UK) with Tris-glycine buffer according
to the supplied manufacturer’s instructions and as described
previously (28–30). Following electrophoresis, the gels were placed
in 10mL of staining solution containing 5mM NAD, 50mM lithium
lactate, 0.1mM Tris-HCl (pH8.6), 0.2mM phenazinmethosulphate
(PMS), 2.0mM nitrobluetetrazolium (NBT) and 0.8mM 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and
the colour was allowed to develop (3–6min) in the dark at 37°C. As-
says were performed to conﬁrm the LDH isoenzyme proﬁles in the
prostate cancer cells, and to correlate these with our NMR ﬁndings.
Assessment of the viability of cells
In order to assess the percentage viability, cells were stained
using trypan blue and counted on a haemocytometer under a
microscope (× 10 objective) to differentiate between nonviable
(blue-stained) and viable (unstained) cells. The viability of cells
both with and without DCA treatment was assessed by culturing
cells in 12-well plates following 3days of growth. Following 24h of
DCA treatment, cells were stained using trypan blue solution, and
the numbers of live and dead cells were counted as described
above. In addition, the viability of cells was measured before and
at 1h after entry into the MR-compatible bioreactor system to esti-
mate the rate of cell death caused by the NMR procedure. Cells were
pipetted from the bioreactor and stained with trypan blue solution,
from which the numbers of dead and living cells were counted.
Bioreactor system
The design of the bioreactor was based on previously published
designs (18,31,32), and consisted of a 5-mm-diameter NMR tube,
which was initially ﬁlled to a depth of 20mm with glass beads
(Fig. 2) to ensure that cells were positioned in the sensitive
region of the NMR coil (18). The phosphate-buffered saline-
rinsed cell suspension of approximately 1mL (which varied in
cell number from 2.5 × 107 to 1.1 × 108 cells/mL) was then
pipetted into the NMR tube. A 1-mm outer diameter coaxial tube
containing 20mM trimethylsilyl propionate (TSP) (dissolved in
D2O) was inserted into the 5-mm NMR tube and used as a
chemical shift reference; 2mL of DMEM medium were pipetted
on top of the cell suspension. A 0.96-mm outer diameter
capillary tube (Smiths Medical, Ashford, Kent, UK), which
provided air (21% oxygen) at a rate of 2.4mL/min via a
diaphragm pump, was then ﬁxed on the top of the 5-mm NMR
tube and placed with the exit approximately 10mm above the
top of the cell suspension. Temperature was controlled by the
9.4-T Bruker Avance III NMR Spectrometer (Bruker Biospin MRI
GmbH, Ettlingen, Germany), set at 310 K and allowed to stabilise
for 30min prior to loading the bioreactor system.
NMR data acquisition and analysis
All spectra were acquired using a Bruker 5-mm BBO probe. Water
signal suppression was achieved using the Watergate suppres-
sion sequence (NUC1 = 1H; NS = 64; DS = 2; spectral width, 11
160Hz; AQ= 0.2 s; D1= 2 s; total time for spectral acquisition,
148 s). The Watergate zggpw5 sequence uses a hard 90° excita-
tion pulse, followed by two composite radiofrequency pulses
comprising ﬁve symmetrical pairs of pulses with different ﬂip
angles. Each composite pulse is surrounded by a pair of
dephasing/rephasing gradients. The effect of the sequence is
to effectively eliminate the water peak, whilst uniformly exciting the
rest of the required spectrum. The ﬂat excitation bandwidth of the
sequence is determined by the spacing of the composite pulses
and the acquisition window. Bruker Topspin 2.1 software was used
for Fourier transform, automatic phasing, baseline correction to help
remove broad baseline signals from macromolecules, line broaden-
ing (1Hz) and zero ﬁlling. Chemical shifts were referenced by setting
the TSP peak to 0ppm or the lactate peak chemical shift conﬁrmed
by two-dimensional double quantum-ﬁltered COrrelated Spectros-
copY (DQF-COSY) and 1H–13C heteronuclear single quantum coherence
(HSQC) assignment, which showed two peaks at 1.3 and 4.11ppm.
Spectral regions of interest were identiﬁed and then integrated
automatically using Bruker TopSpin software.
Metabolite ratio calculations and analysis
Major metabolite spectral regions were identiﬁed from 1H–1H
DQF-COSY and 1H–13C HSQC spectra against the Spectral Data-
base for Organic Compounds (SDBS, sdbs.riodb.aist.go.jp) and
quantiﬁed. Lactate, alanine creatine + phosphocreatine and
choline+glycerophosphocholine were used to form metabolite
ratios. The integration limits were assigned as follows: lactate,
1.25–1.35ppm; alanine, 1.35–1.5 ppm; creatine+phosphocreatine,
2.95–3.05ppm; choline+glycerophosphocholine, 3.15–3.3 ppm.
The assigned compound names are nominal and the integral
regions also contain unidentiﬁed peaks. Metabolite ratios for
lactate/creatine (Lac/Cr), lactate/choline (Lac/Cho) and choline/
Figure 2. Schematic diagram of the bioreactor.
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creatine (Cho/Cr) were calculated and analysed statistically using
SPSS 20 (IBM, London, UK). In addition, a combined metabolite
ratio marker comprising lactate/(choline+ creatine+ alanine)
[Lac/(Cho+Cr+Ala)] was compared between cell types, with
and without treatment. The TSP chemical shift reference peak at
0ppm is also shown, although this was not used as a concentra-
tion standard because of inconsistent radiofrequency excitation
by the Watergate pulse at this frequency, which was near to the
second null of the excitation proﬁle. The glucose region, gluta-
mate/glutamine and leucine, isoleucine and valine regions of the
spectrum were not included in the analysis because of possible
interference from the DMEM solution required to maintain cell
viability (see Discussion).
Statistical analysis
An independent samples, Mann–Whitney, nonparametric, single-
sided U-test was used to assess statistical signiﬁcance at a level
of p< 0.05 between cell types and treatment as the data were
non-normally distributed. For the combined metabolite ratio
marker, a multiple comparison correction was not required. For
cell viability, data were also non-normally distributed, and thus
Kruskal–Wallis and Mann–Whitney tests were used to compare
differences, also at a signiﬁcance level of p< 0.05, applying a
Bonferroni correction for the number of tests.
RESULTS
Cell viability
Similar growth rates for LNCaP-LN3 and LNCaP cells were found
over 4 days. Figure 3 shows that the viability of cells tended to
decrease slightly following DCA treatment for both LNCaP and
LNCaP-LN3 cells; however, this was found not to be statistically
signiﬁcant between the four groups (p> 0.5). In addition, the vi-
ability of cells measured after 1 h in the bioreactor system
showed that the mean cell death across the groups was 2 ± 1%.
Effect of DCA on metabolite ratios
Spectral peaks, identiﬁed from the 1H spectrum shown in Fig. 4,
were integrated to produce metabolite Lac/Cr, Lac/Cho and Lac/
Ala ratios. For LNCaP-LN3 cells, Lac/Cr, Lac/Cho and Lac/Ala were
all signiﬁcantly different following treatment (data not shown). In
addition, the change in the combined metabolite ratio marker
Lac/(Cho +Cr + Ala) also reached signiﬁcance for LNCaP-LN3 cells
following treatment. No metabolite ratios were signiﬁcantly
different following treatment of the LNCaP cells. There were also
no signiﬁcant differences for untreated LNCaP-LN3 and LNCaP
cells. Figure 5 shows the Lac/(Cho +Cr + Ala) metabolite ratios
with median (column) and 95% conﬁdence intervals (bars) plot-
ted for the LNCaP-LN3 and LNCaP cells, before and after
treatment with 50mM DCA.
LDH zymography
The LDH isoenzyme expression in LNCaP-LN3 and LNCaP cancer
cell lines is shown in Fig. 6. Expression of all ﬁve LDH isoenzymes
(LDH-1, LDH-2, LDH-3, LDH-4 and LDH-5) can be seen in LNCaP
cells, whereas absent or reduced expression of isoenzymes
LDH-1, LDH-2, LDH-3 and LDH-4 can be seen in LNCaP-LN3 cells.
These results conﬁrm previous ﬁndings for these cell lines (29).
DISCUSSION
Our results demonstrate similar levels of lactate/metabolite
ratios in two untreated prostate cancer cell lines with very
different metastatic potentials. In contrast, there were differ-
ences in the response of the cell lines to DCA, with several of
the measured lactate/metabolite ratios signiﬁcantly decreased
Figure 3. Plot showing the median and range of viability of cells by cell
type and treatment prior to entry into the bioreactor. Each point repre-
sents an individual experiment. The untreated LNCaP-LN3 and LNCaP
cells showed similar maximum viability values. A Kruskal–Wallis test
showed that there was no signiﬁcant difference in viability between
the four treatment groups (p> 0.5).
Figure 4. Lactate dehydrogenase (LDH) isoenzyme assay of the LNCaP
and LNCaP-LN3 cell lines. A representative example from one of three
experiments is shown. It should be noted that the LDH-5 isoenzyme is pre-
dominantly expressed in the LNCaP-LN3 cells, whereas all ﬁve isoenzymes
(LDH-1–5) are expressed in the LNCaP cells. Equal amounts of protein were
loaded for both cell lines.
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after DCA treatment in the highly metastatic LNCaP-LN3 cells,
but not in the poorly metastatic LNCaP cells. These differences
may relate to a higher prevalence of LDH-A subunits in the
LDH isoenzyme, seen in LNCaP-LN3 relative to LNCaP cells.
Following 1 h after cell entry into the bioreactor system,
viability was assessed and a mean cell death across groups of
2 ± 1% was noted. This meant that cells were still alive during
data acquisition, and therefore our data can be used for the
measurement and interpretation of active cell metabolite ratios.
Some spectral interference from diffusion of the support
medium DMEM into the active MR coil volume containing the
cells, required to maintain cell viability, would be expected. The
partial volume of DMEM in the active coil region during acquisi-
tion has been estimated to be 10% of the cell volume using the
known concentration of glucose of 25mM in DMEM and the
volume and concentration (20mM) of TSP contained within the
tube. DMEM contains many of the same metabolic substances
as found in cells, but most of the relevant amino acids and
support compounds are at concentrations much less than 1mM
(www.sigma-aldrich.com). Therefore, because of the partial
volume factor, they would not contaminate the measured
spectra signiﬁcantly. An exception is D-glucose, which is present
in DMEM at a very high concentration of 25mM. In terms of
amino acids, L-glutamine is the other high-concentration constit-
uent of DMEM at 4mM, and leucine, isoleucine and valine are
present at 0.8mM. For this reason, the glucose, glutamine and
leucine, isoleucine and valine regions of the spectra were not
included in the analysis. All the other compounds in DMEM are
at very low concentrations and so would not be expected to
affect the measured spectra signiﬁcantly.
As expected, the LNCaP-LN3 cells principally showed the
expression of the LDH-5 (LDH-A4) isoenzyme, with relatively
reduced/absent expression of isoenzymes 1–4 (Fig. 6). This ﬁnd-
ing is consistent with the absent or reduced expression of the
LDH-B subunit in LNCaP-LN3 cells, as reported previously (29).
Loss of the LDH-B subunit in prostate, breast and gastric cancers
has been reported to involve promoter hypermethylation
(29,30,33). The remaining LDH-5 isoenzyme is composed solely
of four LDH-A subunits (LDH-A4) (10,34). Thus, considering the
very different LDH isoenzyme proﬁles of our cell lines, our
ﬁnding of no signiﬁcant differences in lactate/metabolite ratios
between the highly metastatic LNCaP-LN3 cells and the poorly
metastatic LNCaP cells was somewhat unexpected. A possible
explanation for this is that the LNCaP cells rely heavily on
processes such as glutamine metabolism to generate lactate
(12,13). It is also possible that any differences in lactate/metab-
olite ratios between the LNCaP and LNCaP-LN3 cells would only
become evident following hypoxic growth conditions, as
shown recently using breast cancer cell lines that lack the
LDH-B subunit (29).
Although a concentration standard (20mM TSP) was included
within the acquisition volume, absolute concentrations were
not used in the analysis because the Watergate water suppres-
sion sequence second excitation null partially suppressed the
0-ppm region of the spectrum. For this reason, we used TSP
purely as a chemical shift reference.
Following DCA treatment, the Lac/Cr, Lac/Cho and Lac/Al
ratios all decreased signiﬁcantly in the highly metastatic
LNCaP-LN3 cells. Cho/Cr was not changed signiﬁcantly using
the same test. The combined metabolite ratio marker Lac/(Cho+
Cr +Ala) was also signiﬁcantly different (p< 0.05). Using the
Figure 5. Example of representative high-resolution 1H spectrum from LNCaP-LN3 cells following 24 h of treatment with 50mM dichloroacetate (DCA) with
nominal assignment labels. Some regions contain unidentiﬁed peaks. TSP, trimethylsilyl propionate.
Figure 6. Combined metabolite ratio marker [lactate/(choline+ creatine+
alanine), Lac/(Cho+Cr+ Ala)] for LNCaP-LN3 cells pre- (n =6) and post-
treatment (n=4) and LNCaP cells pre- (n=3) and post-treatment (n= 3)
with 50mM dichloroacetate (DCA) for 24 h before measurement.
Columns represent median ratios±95% conﬁdence intervals. The only sig-
niﬁcant difference in the nonparametric Mann–Whitney U-test (p<0.05)
was between pre- and post-treatment with DCA of LNCaP-LN3 cells.
M. KAILAVASAN ET AL.
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combined marker removes the need for a multiple comparison
correction. Conversely, no changes in metabolite ratios were
noted following DCA treatment of LNCaP cells. Increased sensi-
tivity of LNCaP-LN3 relative to LNCaP cells may relate to their
LDH isoenzyme proﬁle, which suggests that they rely heavily
on lactate production for their survival and proliferation. Clearly,
further studies are required to substantiate the negative effect of
DCA on LNCaP cells and to investigate the exact mechanism(s)
underlying the differences between the two cell types.
DCA treatment is expected, from other studies, to lead to an
increased ﬂux through the tricarboxylic acid (TCA) cycle and to
induce oxidative stress (35). It has been shown that DCA can
act to facilitate apoptosis of prostate cancer cells (27), and a
previous study has demonstrated 25% inhibition of cell growth
following 96 h of 1mM and 0.5mM DCA in two prostate cancer
cell lines, PC-3-Bcl-2 and PC-3-Neo. Another study, which used
hypoxic HeLA cervical and PANC-1 pancreatic cancer cells to
evaluate in vitro effects of DCA, concluded that, following 24 h
of treatment, 94% of the cells were viable at doses of 12.5mM,
whereas, at 96 h of treatment, only 64% were viable (36).
Furthermore, in HT29 and LoVo cell lines isolated from colorec-
tal adenocarcinomas, there were increases of 2.8% and 21%,
respectively, in total apoptotic cells following 50mM of DCA
treatment for 48 h (37). Based on these reported studies, DCA
toxicity requires signiﬁcant time to manifest, and this could
explain why we only saw a tendency towards decreased
viability after 24 h of treatment in our cell lines. Further studies
are required to determine whether longer exposures to DCA
would induce selective toxicity in the metabolically sensitive
LNCaP-LN3 cell line.
The importance of lactate in tumour progression, including in
prostate cancer development, has been established in many
studies. For instance, lactate has been associated with a low
extracellular pH in tumours, which can increase extracellular ma-
trix breakdown and aid in the regulation of angiogenic factors,
such as vascular endothelial growth factor (VEGF) and interleu-
kin-8 (38). In addition, human studies have shown a strong corre-
lation between tumour lactate concentration following biopsy
and the incidence of metastasis (39).
These considerations have led to a major worldwide research
effort into the targeting of the abnormal metabolism of tumours
for therapeutic beneﬁt. Treatment with doses of DCA as high as
125mg/kg/day have been used in humans for conditions such
as lactic acidosis, although some studies have reported peripheral
nerve effects with doses as low as 25mg/kg/day. DCA mainly has
an effect on cell metabolism, enhancing the entry of pyruvate into
the TCA cycle through repolarisation of the cell membrane, rather
than reducing cell viability, i.e. it is not speciﬁcally cytotoxic (www.
thedcasite.com/dca_human_studies.html). Although DCA may
prove to be unsuitable for further clinical development, other
routes for the inhibition of PDK are actively underway (40,41).
Numerous preclinical studies with DCA have shown a variable
response between different tumour models, highlighting the
need for predictive biomarkers of efﬁcacy (25–27). Our results
suggest that further investigation of the prevalence of LDH-A
subunits in the LDH isoenzyme of tumour cells, for predicting
the response to PDK inhibitors, is warranted. Despite the fact
that the LDH-A subunit predominates in LDH of LNCaP-LN3
cells, no differences were found in the metabolic proﬁling of
these cells versus the LNCaP cells, although a difference in
response to the effects of DCA was observed for the highly
metastasising cells.
CONCLUSIONS
The highly metastatic LNCaP-LN3 cells appeared to respond
metabolically with an inferred decreased production of lactate
when treated with DCA, whereas the poorly metastatic LNCaP
cells did not. The LDH isoenzyme proﬁle appears to be signiﬁcant
in controlling the response of cells to the effects of treatment with
DCA. These ﬁndings are of importance, given that previous studies
(29) have shown an absence of the LDH-B subunit to be a com-
mon feature of both human prostate and breast cancer cases (30).
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